Abstract
Cognitive impairment (CI) is very common in patients with Parkinson’s Disease (PD) and progressively develops on a spectrum from mild cognitive impairment (PD-MCI) to full dementia (PDD). Identification of PD patients at risk of developing cognitive decline, therefore, is unmet need in the clinic to manage the disease. Previous studies reported that oral microbiota of PD patients was altered even at early stages and poor oral hygiene is associated with dementia. However, data from single modalities often unable to explain complex chronic diseases in the brain and cannot reliably predict the risk of disease progression. Here, we performed integrative metaproteogenomic characterization of salivary microbiota and tested the hypothesis that biological molecules of saliva and saliva microbiota dynamically shift in association with the progression of cognitive decline and harbor discriminatory key signatures across the spectrum of CI in PD. We recruited a cohort of 115 participants in a multi-center study and employed multi-omics factor analysis (MOFA) to integrate amplicon sequencing and metaproteomic analysis to identify signature taxa and proteins in saliva. Our baseline analyses revealed contrasting interplay between the genus Neisseria and Lactobacillus and Ligilactobacillus genera across the spectrum of CI. The group specific signature profiles enabled us to identify candidate biomarkers including 7 bacterial genera (Neisseria, Lactobacillus, Rothia, Ligilactobacillus, Alloprevotella, TM7x and Corynebacteirum) and 4 protein groups (40S ribosomal protein SA, 40S ribosomal protein S15, pyruvate, phosphate dikinase and bactericidal permeability-increasing protein) discriminating CI stages in PD (AUC 0.74-0.86). Our study describes compositional dynamics of saliva across the spectrum of CI in PD and paves the way for developing novel, non-invasive biomarker strategies to predict the risk of CI progression in PD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant to Suleyman Yildirim from the Scientific and Technological Research Council of Turkiye (TUBITAK) (grant no. 315S301)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ISTANBUL MEDIPOL UNIVERSITY NON-INTERVENTIONAL CLINICAL TRIALS ETHICS COMMITTEE gave approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The 16S rRNA gene amplicon sequencing data produced in this study have been deposited in the NCBI Sequence Read Archive database under accession no. PRJNA913682
